» Articles » PMID: 31096162

ROS-responsive Nanoparticles Based on Amphiphilic Hyperbranched Polyphosphoester for Drug Delivery: Light-triggered Size-reducing and Enhanced Tumor Penetration

Overview
Journal Biomaterials
Date 2019 May 17
PMID 31096162
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Up to now, limited tumor penetration and poor therapeutic efficiency of drug-loaded nanoparticles are still the major challenges in nanomedicines for cancer chemotherapy. In photodynamic therapy, photosensitizers are often used to generate cytotoxic reactive oxygen species to kill cancer cells. Here, we report a kind of ROS-responsive nanoparticles with light-triggered size-reducing for enhanced tumor penetration and in vivo drug delivery to improve therapeutic efficiency. The nanoparticles were constructed by the self-assembly of an amphiphilic hyperbranched polyphosphoester containing thioketal units and photosensitizers, which is synthesized through the self-condensing ring-opening polymerization of a novel cyclic phosphate monomer and then end-capped with photosensitizer Chlorin e6. These nanoparticles have an initial averaged diameter of ∼210 nm, which can be used as drug carriers to load camptothecin with relatively stable in blood circulation. The CPT-loaded nanoparticles can be concentrated in tumor tissues through the long blood circulation and enhanced permeability and retention effect. Upon 660 nm laser irradiation on tumor tissues, the Ce6s in nanoparticles can effectively generate ROS to kill cancer cells meanwhile cleave the thioketal units to sequentially reduce the size of nanoparticles, which facilitate them more efficient tumor penetration with a programmable release of CPT. Both in vitro and in vivo studies confirmed the above results. Such ROS-responsive nanoparticles with light-triggered size-reducing provided a feasible approach to improve drug tumor penetration and achieve satisfied therapeutic efficacy.

Citing Articles

Tumor microenvironment-responsive hyperbranched polymers for controlled drug delivery.

Guo Y, He X, Williams G, Zhou Y, Liao X, Xiao Z J Pharm Anal. 2025; 14(12):101003.

PMID: 39831051 PMC: 11742316. DOI: 10.1016/j.jpha.2024.101003.


Deformable nanocarriers for enhanced drug delivery and cancer therapy.

Cao Z, Liu J, Yang X Exploration (Beijing). 2024; 4(5):20230037.

PMID: 39439489 PMC: 11491306. DOI: 10.1002/EXP.20230037.


Fabrication of polymeric sorafenib coated chitosan and fucoidan nanoparticles: Investigation of anticancer activity and apoptosis in colorectal cancer cells.

Zhou Y, Liu J, Ma S, Yang X, Zou Z, Lu W Heliyon. 2024; 10(14):e34316.

PMID: 39130440 PMC: 11315206. DOI: 10.1016/j.heliyon.2024.e34316.


Fabrication of folic acid-modified bovine serum albumin cloaked dual-drug loaded hollow mesoporous silica nanoparticles for pH-responsive and targeted delivery of gastric cancer therapy.

Zhang Y, Liang Y Heliyon. 2024; 10(8):e29274.

PMID: 38699737 PMC: 11063411. DOI: 10.1016/j.heliyon.2024.e29274.


Enhancing drug penetration in solid tumors via nanomedicine: Evaluation models, strategies and perspectives.

Shen X, Pan D, Gong Q, Gu Z, Luo K Bioact Mater. 2023; 32:445-472.

PMID: 37965242 PMC: 10641097. DOI: 10.1016/j.bioactmat.2023.10.017.